Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Anastrozole & Breast Cancer / Mammacarcinoma (HR+ Her2-)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Anastrozole is a cornerstone therapy for Breast cancer / Mammacarcinoma (HR+ Her2-), mechanistically acting via aromatase inhibition and direct Estrogen receptor alfa interaction, and is endorsed by global clinical and regulatory guidelines for this patient population (1-4).

References:

(1) Cuzick et al. 2020
(2) Lammers et al. 2024 Breast Cancer Res Treat 208(1): 179-192
(3) Buzdar 2001 Br J Cancer 85(Suppl 2): 6-10
(4) Hunt et al. 2023 Ann Surg Oncol 30: 2111-2118

…

References (Sources)

Anastrozole (Arimidex) - an aromatase inhibitor for the adjuvant setting?
Buzdar 2001 Br J Cancer 85(Suppl 2): 6-10
Review
Health‐Related Quality of Life in MONARCH 3: Abemaciclib + an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer
Goetz et al. 2020
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer
Hunt et al. 2023 Ann Surg Oncol 30: 2111-2118
Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial
Lammers et al. 2024 Breast Cancer Res Treat 208(1): 179-192
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
Cuzick et al. 2020

AI Chat

7/1/2026

Chat with our artificial intelligence: